AMEX:SYN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. More Details


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Synthetic Biologics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SYN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.9%

SYN

-3.0%

US Biotechs

-1.3%

US Market


1 Year Return

-19.4%

SYN

33.9%

US Biotechs

18.5%

US Market

Return vs Industry: SYN underperformed the US Biotechs industry which returned 33.9% over the past year.

Return vs Market: SYN underperformed the US Market which returned 18.5% over the past year.


Shareholder returns

SYNIndustryMarket
7 Day-1.9%-3.0%-1.3%
30 Day-33.7%1.8%5.3%
90 Day-38.6%-3.7%7.5%
1 Year-19.4%-19.4%36.2%33.9%21.3%18.5%
3 Year-98.9%-98.9%19.1%13.1%42.4%32.9%
5 Year-99.6%-99.6%15.2%7.0%84.2%63.5%

Price Volatility Vs. Market

How volatile is Synthetic Biologics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Synthetic Biologics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Synthetic Biologics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Synthetic Biologics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Synthetic Biologics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-5.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SYN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SYN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SYN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if SYN's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if SYN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SYN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Synthetic Biologics performed over the past 5 years?

17.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SYN is currently unprofitable.

Growing Profit Margin: SYN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SYN is unprofitable, but has reduced losses over the past 5 years at a rate of 17.7% per year.

Accelerating Growth: Unable to compare SYN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SYN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: SYN has a negative Return on Equity (-243.46%), as it is currently unprofitable.


Next Steps

Financial Health

How is Synthetic Biologics's financial position?


Financial Position Analysis

Short Term Liabilities: SYN's short term assets ($9.0M) exceed its short term liabilities ($3.4M).

Long Term Liabilities: SYN's short term assets ($9.0M) exceed its long term liabilities ($334.0K).


Debt to Equity History and Analysis

Debt Level: SYN is debt free.

Reducing Debt: SYN has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SYN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SYN has less than a year of cash runway if free cash flow continues to grow at historical rates of 8% each year.


Next Steps

Dividend

What is Synthetic Biologics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SYN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SYN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SYN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SYN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SYN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average board tenure


CEO

Steve Shallcross (59 yo)

2.83yrs

Tenure

US$1,108,609

Compensation

Mr. Steven A. Shallcross, also known as Steve, CPA, has been Independent Director of Newgioco Group, Inc. since June 13, 2019. Mr. Shallcross has been the Chief Financial Officer, Treasurer and Secretary a ...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD1.11M) is above average for companies of similar size in the US market ($USD589.00K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Steven Shallcross
CEO, CFO2.83yrsUS$1.11m0.26%
$ 16.4k
Scott Tarriff
Independent Director8.67yrsUS$132.00k0.044%
$ 2.8k
Jeffrey Kraws
Independent Non-Executive Chairman8.42yrsUS$242.00k0.034%
$ 2.1k
Jeffrey Wolf
Independent Director14.75yrsUS$140.00kno data
Curtis Donskey
Member of C Difficile Clinical Advisory Board6.33yrsno datano data
Thomas Louie
Member of C Difficile Clinical Advisory Board6.33yrsno datano data
William Chey
Member of C-IBS Clinical Advisory Board6yrsno datano data
Ciarán Kelly
Member of C Difficile Clinical Advisory Board6.33yrsno datano data
Mark Wilcox
Chairman of C Difficile Clinical Advisory Board6.33yrsno datano data
Mark Pimentel
Chairman of C-IBS Clinical Advisory Board6.5yrsno datano data
Gail Comer
Member of C-IBS Clinical Advisory Board6yrsno datano data
Charles Shoemaker
Member of Infectious Disease Scientific Advisory Board8yrsno datano data

6.3yrs

Average Tenure

58yo

Average Age

Experienced Board: SYN's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.7%.


Top Shareholders

Company Information

Synthetic Biologics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Synthetic Biologics, Inc.
  • Ticker: SYN
  • Exchange: AMEX
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$6.388m
  • Shares outstanding: 19.44m
  • Website: https://www.syntheticbiologics.com

Number of Employees


Location

  • Synthetic Biologics, Inc.
  • 9605 Medical Center Drive
  • Suite 270
  • Rockville
  • Maryland
  • 20850
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SFYCDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2006
SYNAMEX (NYSE MKT LLC)YesCommon StockUSUSDNov 2006

Biography

Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II cl ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/21 00:40
End of Day Share Price2020/10/20 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.